A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
About this trial
This is an interventional treatment trial for Secondary Progressive Multiple Sclerosis focused on measuring Secondary Progressive Multiple Sclerosis, Neuroprotection, Axonal loss, Brain atrophy, MRI, Lamotrigine, Sodium Channel Blockers
Eligibility Criteria
Inclusion Criteria: Age 18 to 60 Progression rather than clinical relapse is the major cause for increased disability over the preceding 2 years EDSS 4.0-6.5 Exclusion Criteria: Very rapid deterioration in EDSS, >2 points over 6 months Use of Mitoxantrone in the preceding year Use of sodium channel blockers or calcium channel blockers in the preceding 2 weeks Use of corticosteroids in preceding 2 months Use of neuroprotective agents or immunosuppressants in the preceding 6 months Evidence of significant hepatic or renal impairment either in clinical history or blood results. Prior untoward reactions to lamotrigine, or severe temperature dependent symptoms Contraindications to MRI
Sites / Locations
- National Hospital for Neurology and Neurosurgery